Skip to main content

Effect of Dose Interval on Split-dose Bowel Preparation: A Multicenter Noninferiority Randomized Controlled Trial

In brief

Oral sulfate bowel prep achieved adequate cleansing in 96% with either timing

In a 17-center randomized trial of 551 people, bowel preparation was adequate in 96.0% with doses 6 to 8 hours apart and 96.7% with doses 10 to 12 hours apart, meeting the study's noninferiority finding. Polyp and adenoma detection, side effects, and blood electrolyte changes were also similar; the results support flexible timing, though the trial tested one preparation in China.

Journal
Gastrointestinal endoscopy (Q1)
Published
12 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Xiangyu Sui, Yi Zeng, Jiahui Wei, Song Zhang, Jiemin Hong, Xiaobin Sun, et al.
PMID
43020140
DOI
10.1016/j.gie.2026.11.013

Why clinicians should know about it

  • Picked for Gastroenterology (top studies of the week, 15 November 2026): Multicenter trial informs split-dose bowel preparation timing and colonoscopy quality

Abstract

BACKGROUND AND AIMS: Although split-dose bowel preparation is recommended to optimize colon cleansing, no standardized dosing regimen has been established. This study aimed to evaluate whether long/short dose intervals of oral sulfate solution (OSS) affect the bowel preparation quality in the split-dose regimen. METHODS: A multicenter, noninferiority randomized controlled trial (SUPERCLEAN) was conducted across 17 centers in China. Participants were randomized 1:1 into either the short-interval group, with a 6-8 hours interval between doses, or the long-interval group, with a 10-12 hours interval. The primary outcome was the rate of adequate bowel preparation. RESULTS: A total of 551 participants were included in the intention-to-treat (ITT) set and randomized into the short-interval group (n=276) and the long-interval group (n=275). The per-protocol (PP) analysis included 430 participants. In the ITT analysis, adequate bowel preparation rate of the short-interval group was not inferior to the long-interval group (96.0% vs. 96.7%, P=0.655), with a difference of -0.7% (95% CI: -3.8% to 2.4%). Similar results were observed in the PP analysis (97.2% vs. 98.6%, difference= -1.4%, 95% CI: -4.2% to 1.3%, P = 0.474). No significant differences were observed in polyp detection rate (55.5% vs. 56.3%, P=0.855), adenoma detection rate (33.9% vs. 37.9%, P=0.339), adverse events (35.0% vs. 30.5%, P=0.260), and changes in peripheral blood electrolytes (all P > 0.05) between the short and long-interval groups. CONCLUSIONS: The short and long dose intervals of OSS showed comparable efficacy and safety in split-dose regimen, supporting flexible administration timing without compromising bowel preparation quality.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.